ABSTRACT
Microbial cell-free DNA (mcfDNA) sequencing is a promising tool to identify infectious pathogens when traditional methods fail to identify the causative agent. We performed a retrospective observational cohort study to evaluate clinical outcomes among pediatric and adult patients who underwent mcfDNA testing. 127 mcfDNA tests were reviewed from 112 patients. Baseline characteristics included 61 (54.5 %) adults, 52 (40.9 %) tests were from female patients, and 67 (52.8 %) tests were obtained from patients designated as immunocompromised. Of all tests obtained, 59 (46.4 %) were deemed clinically relevant. 41 (32.3 %) of tests also led to a change in antimicrobial management for the corresponding patient. No statistically significant association was ascertained between patient-specific factors and clinically relevant test results. Testing in certain clinical scenarios or high-risk settings may be useful, however further studies are needed to assess the cost-benefit of this approach.
Subject(s)
Cell-Free Nucleic Acids , Communicable Diseases , High-Throughput Nucleotide Sequencing , Humans , Female , Retrospective Studies , High-Throughput Nucleotide Sequencing/methods , Male , Adult , Child , Middle Aged , Adolescent , Cell-Free Nucleic Acids/blood , Child, Preschool , Young Adult , Communicable Diseases/diagnosis , Communicable Diseases/drug therapy , Communicable Diseases/microbiology , Aged , Infant , Molecular Diagnostic Techniques/methods , Aged, 80 and overABSTRACT
Coccidioidomycosis is a fungal infection with a range of clinical manifestations. Currently used antifungal agents exhibit variable efficacy and toxicity profiles that necessitate evaluation of additional therapeutic options. Improvement was observed in the majority of patients treated with isavuconazole, with clinical failures observed only in those with coccidioidal meningitis.
Subject(s)
Coccidioidomycosis , Humans , Coccidioidomycosis/drug therapy , Coccidioidomycosis/microbiology , Coccidioides , Triazoles/therapeutic use , Antifungal Agents/therapeutic useABSTRACT
Mpox has recently re-emerged as a global entity of concern. We report one of the first pediatric cases in the United States and provide updated recommendations relevant to infection control and prevention measures of those in close contact with mpox.